126 related articles for article (PubMed ID: 38372205)
41. Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
Zheng LP; Chen LY; Liao XY; Xu ZH; Chen ZT; Sun JG
BMC Cancer; 2018 Nov; 18(1):1070. PubMed ID: 30400855
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Ma Y; Shi H; Du Y; Huang Y
Sci Rep; 2018 Oct; 8(1):15426. PubMed ID: 30337598
[TBL] [Abstract][Full Text] [Related]
43. Invertase-labeling gold-dendrimer for in situ amplified detection mercury(II) with glucometer readout and thymine-Hg(2+)-thymine coordination chemistry.
Qiu Z; Shu J; Jin G; Xu M; Wei Q; Chen G; Tang D
Biosens Bioelectron; 2016 Mar; 77():681-6. PubMed ID: 26496222
[TBL] [Abstract][Full Text] [Related]
44. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
Xu J; Zhu GY; Cao D; Pan H; Li YW
Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
[TBL] [Abstract][Full Text] [Related]
45. CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
Suryavanshi M; Jaipuria J; Panigrahi MK; Goyal N; Singal R; Mehta A; Batra U; Doval DC; Talwar V
Lung Cancer; 2020 Oct; 148():33-39. PubMed ID: 32784073
[TBL] [Abstract][Full Text] [Related]
46. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
[TBL] [Abstract][Full Text] [Related]
47. Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.
Piotrowska Z; Drapkin B; Engelman JA; Nagy RJ; Lanman RB; Sequist LV
J Thorac Oncol; 2016 Aug; 11(8):e95-e97. PubMed ID: 27079185
[No Abstract] [Full Text] [Related]
48. Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
Nargesi S; Dolatshahi Z; Rezapour A; Alipour V; Souresrafil A; Farabi H; Javadmoosavi SA; Safakhah M; Moradi N
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):543-554. PubMed ID: 34846235
[TBL] [Abstract][Full Text] [Related]
49. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
50. EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits.
Bencze E; Bogos K; Kohánka A; Báthory-Fülöp L; Sárosi V; Csernák E; Bittner N; Melegh Z; Tóth E
Pathol Oncol Res; 2022; 28():1610607. PubMed ID: 36277960
[No Abstract] [Full Text] [Related]
51. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
[TBL] [Abstract][Full Text] [Related]
52. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
53. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
54. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.
Liu B; Gao F; Zhao H; Yuan S; Peng X; Zhang P; Wang J; Zhang T; Duan M; Guo Y
Eur J Med Chem; 2023 Oct; 258():115590. PubMed ID: 37406381
[TBL] [Abstract][Full Text] [Related]
55. Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.
Oh YH; Kim Y; Kim YP; Seo SW; Mitsudomi T; Ahn MJ; Park K; Kim HS
J Mol Diagn; 2010 Sep; 12(5):644-52. PubMed ID: 20805561
[TBL] [Abstract][Full Text] [Related]
56. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
57. [Non-Small Cell Lung Cancer - Development of Parallel Mechanisms of Resistance].
Moeller M; Siebolts U; Wickenhauser C; Schuette W
Pneumologie; 2018 Jul; 72(7):503-506. PubMed ID: 29466812
[TBL] [Abstract][Full Text] [Related]
58. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
60. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]